Proteomic Analysis of Terminalia chebula Extract-Dependent Changes in Human Lymphoblastic T Cell Protein Expression

Abstract

Terminalia chebula is a native plant from southern Asia to southwestern China that is used in traditional medicine for the treatment of malignant tumors and diabetes. This plant also has antibacterial and immunomodulatory properties. The present study assessed T. chebula extract-dependent protein expression changes in Jurkat cells. Matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry and Ingenuity Pathways Analysis (IPA) were performed to assess protein expression and networks, respectively. A comparative proteomic profile was determined in T. chebula extract (50 μg/mL)-treated and control cells; the expressions of β-tubulin, ring finger and CHY zinc finger domain containing 1, and insulin-like growth factor 1 receptor kinase were significantly down-regulated in T. chebula extract-treated Jurkat cells. Moreover, the molecular basis for the T. chebula extract-dependent protein expression changes in Jurkat cells was determined by IPA. Treatment with the T. chebula extract significantly inhibited nuclear factor-κB activity and affected the proteomic profile of Jurkat cells. The molecular network signatures and functional proteomics obtained in this study may facilitate the evaluation of potential antitumor therapeutic targets and elucidate the molecular mechanism of T. chebula extract-dependent effects in Jurkat cells.

The medicinal properties and phytochemistry of plants of the genus Terminalia (Combretaceae)

“…In vivo administration of sericoside to Sprague-Dawley rats prior to IBD induction results in a significant reduction in neutrophil activation and infiltration into the colon mucosa (Mochizuki and Hasegawa 2007). Furthermore, chebulagic acid isolated from T. chebula decreases cytokine production and IL-6 expression in human lymphoblastic T lymphocytes (Das et al 2012), thereby decreasing chemotaxis. T. chebula extract treatment also results in decreased expression levels of TNF-a in Jurkat cells, which would subsequently downregulate other cytokines including IL-1 and IL-6 (Lin et al 2010.…”

Endophytic Fungi from Terminalia Species: A Comprehensive Review

“…Members of the genus Terminalia have a long history in traditional medicinal systems since they are widely used in several continents for the treatment of numerous diseases, including cardiovascular effects [12], wound healing [13], abdominal disorders, bacterial infections, colds, sore throats, conjunctivitis, diarrhoea, dysentery, fever, gastric ulcers, headaches, heart diseases, hookworm, hypertension, jaundice, leprosy, nosebleed, edema, pneumonia and skin diseases [14,15]. Apart from their ethnopharmacological usage, several pharmacological properties, including antibacterial [16,17], antifungal [18], antiprotozoal [19,20], antiviral [21,22], antidiarrhoeal [23], analgesic [24], antimalarial [25,26], antioxidant [27,28], anti-inflammatory [29,30,31], antidiabetic [32,33], antihyperlipidemic [34,35], anticancer [36,37,38], and anti-HIV [25,39] activities—as well as several bioactive compounds—have been reported from some of these species [17]. However, even though several authors have reviewed the phytochemistry, pharmacological activities, and ethnopharmacological usage of the Terminalia species, no review on the Terminalia’s endophytic fungi and their bioactive compounds has been reported, to the best of our knowledge.…”